Durvalumab, an anti-PDL1, has also been used in combination with dabrafenib and trametinib in patients with both BRAF-mutated and BRAF-wild-type advanced melanoma [166] in a phase I clinical trial (NCT02027961). Here, BRAF is linked to melanoma.